Find recruiting clinical trials for blood cancers and disorders in the UK — non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, leukaemias (AML, ALL, CLL), MDS, myeloma, and more. See treatment pathways and where trials fit in.
Free to use · Live data from ClinicalTrials.gov · Updated hourly
The most common haematological malignancy. Includes DLBCL, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and T-cell lymphomas.
Highly curable lymphoma, especially in early stages. Relapsed/refractory patients may benefit from novel therapies including checkpoint inhibitors and CAR-T.
Aggressive blood cancer requiring urgent treatment. Rapidly evolving treatment landscape with targeted therapies (FLT3, IDH inhibitors) and novel combinations.
Most common adult leukaemia. Treatment revolutionised by BTK inhibitors (ibrutinib, acalabrutinib) and BCL-2 inhibitor (venetoclax).
Plasma cell cancer with multiple treatment lines. BCMA-targeted therapies (CAR-T, bispecifics) represent the biggest advance in decades.
Myelodysplastic syndromes and myeloproliferative neoplasms. Range from low-risk (observation) to high-risk (approaching AML). Growing trial landscape.
Loading trials from ClinicalTrials.gov...